Together we are stronger

Pharnext’s press release on CMT in Paris

I this occasion, Professor  David R. Cornblath, expert  in peripheral neuropathies including CMT,and Professor of Neurology at Johns Hopkins University in Baltimore, Maryland, U.S.A., took a stock of the latest scientific and medical advances in CMT, from his diagnosis to the various available therapeutic options. This conference also was the opportunity for Pharnext’s management to come back on outcomes of SYNGILITY® (PXT3003), which is the result of Phase 3 pivotal clinic trial on CMT1A disease treatment.

Donations Accepted